ARPA-H POSEIDON Proposers' Day Presentation Video (9/4/24)
POSEIDON (Platform Optimizing SynBio for Early Intervention and Detection in Oncology)
What if a simple test could save millions of lives by catching cancer early?
The Platform Optimizing SynBio for Early Intervention and Detection in ONcology, or POSEIDON, program aims to fundamentally change the field of cancer screening by developing first-in-class, over-the-counter, MCED tests that screen for 30+ cancers at Stage 1. POSEIDON intends to develop non-invasive synthetic sensors and reporters to reliably detect cancer from breath or urine samples at home. The self-administered kit, based on human-centered design, would allow any adult American to screen for cancers before symptoms arise. The kit would also integrate results securely with electronic health records and ensure individuals connect with a health care professional via a telemedicine call to review results.
This revolutionary program seeks to change how and when people are screened for cancer, giving every American the chance to test themselves long before they have symptoms. This paradigm shift will decrease the economic and psychological burden of cancer by identifying tumors early and initiating the path to curative treatments. Additionally, by integrating human-centered design, POSEIDON aims to ensure that its tests are designed by and for all Americans.
Program Manager: Ross Uhrich, DMD, MBA
Learn more at:
https://arpa-h.gov/research-and-fundi...